Before I pass it on to my colleague Majid, I just have a question with regard to something you mentioned. Canada is a small player relative to other bigger nations when it does purchasing, but at the same time, if the private sector does find a vaccine and chooses a market, it will be more attracted, by default, to countries such as, for instance, the U.S., because it has 330 million people versus Canada's with 36 million people. Is there any regulatory change that you would advise Canada to undergo to ensure we become an attractive market for those potential clinical trials or for the miracle vaccine that everybody is working on?
On May 1st, 2020. See this statement in context.